ARCHIVES

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

Docetaxel As Adjuvant Therapy Shows Benefit Over Standard

June 28, 2002

Genomic Health Presents Meta-Analyses of Oncotype DX

January 28, 2011

Four Patients In Tamoxifin Treatment Trial Had Died of Uterine Cancer Prior To BCPT

April 29, 1994

STAR Begins: Critics of Trial Call For Including A Placebo Arm

June 4, 1999

“Spoiled, Petulant Brat”: BioMarin CEO Fires Off Feisty Emails In Battle Over Access to PARP Inhibitor

November 8, 2013

Obituary: Patricia Delaney, FDA Cancer Liaison.

June 6, 2008